clinical trial · NCT04816604
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.·phase2·active not recruiting·n = 74
Pulmonary Arterial HypertensionGB002 (seralutinib)Generic Dry Powder Inhaler
brief summary
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
started
Apr 5, 2021
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Apr 9, 2026
official title
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol